Speed vs. Quality in Early Drug Development: Striking the Right Balance for Antibody Therapeutics

In today’s hyper-competitive drug development landscape, the pressure to accelerate timelines is more intense than ever. Pharma and biotech companies alike are expected to move from antibody discovery to clinical testing with unprecedented speed. Whether driven by internal KPIs, investor expectations, or the race to claim first-in-class status, the demand for fast progress is undeniable.

However, framing speed and quality as opposing forces creates a dangerous misconception. It suggests that developers must choose between rapid advancement and robust science. In truth, sustainable progress requires both. Starting with high-quality, reproducible antibody materials is not a barrier to speed, but the foundation for it. A molecule that performs reliably in early development will scale, comply, and succeed faster in the long run.

This article explores the realities behind the speed-versus-quality debate and outlines strategies to accelerate therapeutic antibody development without compromising rigor.

The race for speed in drug development – benefits and risks

Timelines in drug development are measured not just in months, but in competitive advantage. Fast lead identification, rapid preclinical testing, and early clinical entry can significantly boost a program’s strategic value. But this drive for speed can backfire if it leads to cutting corners. 

Rushed expression protocols, limited characterization, or insufficient developability testing may result in poor expression yields, suboptimal pharmacokinetics, or failure to scale. Even worse, late-stage rework or termination due to early oversight can cost far more than the time saved upfront ¹.

Why quality and reproducibility are non-negotiable from the start

Antibodies that are not properly characterized may behave inconsistently across in vitro and in vivo assays, eroding confidence in data and delaying decision-making. Without reproducibility, comparability across batches or sites becomes a guessing game.

This is particularly critical in antibody and vaccine programs, where batch consistency must be demonstrated across development stages. Regulators expect robust, traceable data starting from discovery. Using well-characterized, reproducible material from the outset helps prevent costly surprises during IND-enabling studies ².

Common misconceptions – speed and quality are not mutually exclusive

Thanks to advances in antibody engineering and production technologies, speed and quality can now be achieved in tandem. High-performance expression systems, such as CHO-based transient platforms, enable rapid, scalable production. At the same time, pairing technologies like evitria’s bYlok® ensure precise bispecific assembly and minimal mispairing.

The key lies in selecting partners and workflows that are built for both speed and precision. Quality should not slow you down; it should make progress smoother, more predictable, and ultimately faster ³.

Practical strategies to accelerate timelines without compromising quality

A high-quality early-stage process does not have to be slow. Consider the following best practices:

• Use CHO-based transient expression systems: These systems combine speed with scalability, avoiding later-stage bridging studies.
  
• Integrate developability assessments early: By screening for aggregation, solubility, and expression levels early, developers can deprioritise candidates with red flags before investing in scale-up.
  
• Employ high-fidelity pairing strategies: Technologies like bYlok®, knobs-into-holes, or CrossMab reduce mispairing and improve downstream purity for bispecifics.
  
• Parallelize critical steps: Overlapping expression, purification, and early bioassays compresses timelines without sacrificing data integrity.
  
• Partner with experienced CDMOs: Working with providers who understand both the urgency and the science can eliminate inefficiencies and avoid common pitfalls.
  
• Apply Quality by Design (QbD) principles: Embedding quality considerations from the start strengthens the entire development chain ⁴.
  

Scalability considerations – thinking beyond early discovery

Some early-stage processes are fast but fragile. They work at microgram scale but collapse when scaled up. That’s why choosing scalable systems like CHO-based transient expression at the beginning is a strategic advantage. It eliminates the need for material bridging or revalidation later on, preserving timelines and data integrity.

Studies show that high-quality transiently expressed antibodies can meet the standards required for clinical evaluation, provided the system is robust. Early investment in scalable, reproducible expression methods leads to smoother transitions to GMP manufacturing, regulatory approval, and commercial production ⁵.

How evitria delivers both speed and reproducibility for therapeutic development

At evitria, our services are designed to help therapeutic developers move fast without compromising on consistency or scalability.

We work with CHO-based transient expression systems that are optimized for reproducible performance. From early microgram-scale testing to gram-level production, we maintain consistent quality across batches to support reliable candidate comparison and preclinical planning.

Our experience includes a wide range of antibody formats: from standard IgGs to bispecific and trispecific constructs, supported by established technologies such as glycoengineering and Fc modifications. In projects where speed is critical, we offer turnaround times starting at four weeks from sequence to delivery, enabling rapid iteration and data-driven decision-making.

By focusing on reproducibility, flexibility, and scientific collaboration, we help our partners reduce risk during early development and build a strong foundation for what comes next.

References:

1. Ecker, D. M., Jones, S. D., and Levine, H. L. “The Therapeutic Monoclonal Antibody Market.” mAbs, vol. 7, no. 1, 2015, pp. 9–14. https://doi.org/10.4161/19420862.2015.989042. ↩︎
2. Raybould, Matthew I J, et al. “Five Computational Developability Guidelines for Therapeutic Antibody Profiling.” PNAS, vol. 116, no. 10, 2019, pp. 4025–4030. https://doi.org/10.1073/pnas.1810576116 ↩︎
3. Madsen, Andreas V., et al. “Design and Engineering of Bispecific Antibodies: Insights and Practical Considerations.” Frontiers in Bioengineering and Biotechnology, vol. 12, 2024, https://doi.org/10.3389/fbioe.2024.1352014. ↩︎
4. Tan, Huanbo, et al. “Recent Advances in Half-Life Extension Strategies for Therapeutic Peptides and Proteins.” Current Pharmaceutical Design, vol. 24, no. 41, 2018, pp. 4932–4946. https://doi.org/10.2174/1381612825666190206105232. ↩︎
5. Rodriguez-Conde, Sara, et al. “Suitability of Transiently Expressed Antibodies for Clinical Studies: Product Quality Consistency at Different Production Scales.” mAbs, vol. 14, no. 1, 2022, p. 2052228. https://doi.org/10.1080/19420862.2022.2052228. ↩︎